论文部分内容阅读
美国银泉医学中心8月10日宣布,美国FDA已经批准雷珠单抗注射液(Lucentis)用于治疗糖尿病性黄斑水肿(DME)。根据该药的批准信息,该药每月经玻璃体内注射一次。患者同时应该控制好血糖。
The Silver Spring Medical Center announced on August 10 that the U.S. FDA has approved the use of Lucentis injection for the treatment of diabetic macular edema (DME). According to the drug’s approval information, the drug is injected intravitreally once a month. Patients should also control the blood sugar at the same time.